Financial Security Advisor Inc. Acquires Shares of 2,475 Hologic, Inc. (NASDAQ:HOLX)

Financial Security Advisor Inc. bought a new stake in Hologic, Inc. (NASDAQ:HOLX) in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 2,475 shares of the medical equipment provider’s stock, valued at approximately $202,000.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Prentiss Smith & Co. Inc. increased its stake in shares of Hologic by 0.3% during the third quarter. Prentiss Smith & Co. Inc. now owns 48,696 shares of the medical equipment provider’s stock worth $3,967,000 after acquiring an additional 130 shares during the period. Massmutual Trust Co. FSB ADV raised its stake in shares of Hologic by 20.3% during the 2nd quarter. Massmutual Trust Co. FSB ADV now owns 831 shares of the medical equipment provider’s stock worth $62,000 after buying an additional 140 shares in the last quarter. Wedmont Private Capital lifted its holdings in shares of Hologic by 3.7% in the 3rd quarter. Wedmont Private Capital now owns 4,519 shares of the medical equipment provider’s stock valued at $361,000 after buying an additional 162 shares during the period. Sequoia Financial Advisors LLC lifted its holdings in shares of Hologic by 2.3% in the 2nd quarter. Sequoia Financial Advisors LLC now owns 7,215 shares of the medical equipment provider’s stock valued at $536,000 after buying an additional 165 shares during the period. Finally, Curbstone Financial Management Corp boosted its stake in shares of Hologic by 0.9% in the second quarter. Curbstone Financial Management Corp now owns 23,126 shares of the medical equipment provider’s stock valued at $1,717,000 after buying an additional 200 shares in the last quarter. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Analyst Upgrades and Downgrades

HOLX has been the subject of a number of recent analyst reports. Raymond James raised their target price on Hologic from $93.00 to $95.00 and gave the company an “outperform” rating in a report on Tuesday. Mizuho reduced their price objective on shares of Hologic from $90.00 to $87.00 and set an “outperform” rating for the company in a research note on Tuesday. Evercore ISI upped their target price on shares of Hologic from $78.00 to $82.00 and gave the stock an “in-line” rating in a research report on Tuesday, October 1st. JPMorgan Chase & Co. boosted their price target on Hologic from $92.00 to $94.00 and gave the stock an “overweight” rating in a research note on Tuesday. Finally, Royal Bank of Canada upped their price target on Hologic from $86.00 to $89.00 and gave the stock a “sector perform” rating in a report on Tuesday. Five investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $89.25.

Hologic Stock Down 5.9 %

Shares of HOLX opened at $78.80 on Wednesday. The firm has a market cap of $18.30 billion, a PE ratio of 26.80, a price-to-earnings-growth ratio of 2.98 and a beta of 0.98. The company has a quick ratio of 3.32, a current ratio of 3.99 and a debt-to-equity ratio of 0.51. The company’s fifty day moving average is $81.05 and its two-hundred day moving average is $78.11. Hologic, Inc. has a fifty-two week low of $66.93 and a fifty-two week high of $84.67.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.01. The firm had revenue of $987.90 million during the quarter, compared to the consensus estimate of $978.25 million. Hologic had a return on equity of 19.53% and a net margin of 17.59%. The firm’s quarterly revenue was up 4.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.89 earnings per share. Analysts forecast that Hologic, Inc. will post 4.09 earnings per share for the current year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.